Table 3.
Primary and secondary clinical endpoints after a follow-up of 5 years
| Endpoint | Tamponade group (n = 200) | Control group (n = 400) | Hazard ratio (95% CI) | P value Cox regression |
|---|---|---|---|---|
| Number (percent) | Number (percent) | |||
| Primary a | 38 (19.0) | 58 (14.5) | 1.22 (0.79–1.88) | 0.382 |
| Secondary | ||||
| Death from any cause | 21 (10.5) | 22 (5.5) | 1.67 (0.89–3.10) | 0.111 |
| Acute myocardial infarction | 4 (2.0) | 6 (1.5) | 1.24 (0.35–4.43) | 0.739 |
| TIA/stroke | 11 (5.5) | 18 (4.5) | 1.26 (0.59–2.70) | 0.549 |
| Hospitalization for heart failure | 15 (7.5) | 23 (5.8) | 1.14 (0.56–2.31) | 0.715 |
| Cardiovascular death | 11 (5.5) | 7 (1.8) | 2.27 (0.84–6.16) | 0.106 |
| Hospitalization for pericarditis | 31 (15.5) | 3 (0.8) | 20.67 (6.32–67.60) | <0.001 |
a
Composite of death from any cause, acute myocardial infarction, TIA/stroke, and hospitalization for heart failure.
CI, confidence interval; TIA, transitory ischaemic attack.